Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
Leggett & Platt reports a one-off $659 million loss, but its adjusted results indicate a return to profitability with improving net margins.
Nicki Minaj's praise of Trump's Nigeria criticism sparks backlash, reigniting debate over her political engagement.
Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
Leggett & Platt reports a one-off $659 million loss, but its adjusted results indicate a return to profitability with improving net margins.
Nicki Minaj's praise of Trump's Nigeria criticism sparks backlash, reigniting debate over her political engagement.